|
|
RALDH2 |
|
Vaxjo ID |
319 |
|
Vaccine Adjuvant Name |
RALDH2 |
|
Description |
Retinaldehyde dehydrogenase 2 (RALDH2) is the rate-limiting enzyme in retinoic acid (RA) biosynthesis, investigated as a molecular adjuvant to enhance mucosal immunity during DNA vaccination. |
|
Stage of Development |
Research |
|
Host Species for Testing |
Mouse |
|
Components |
DNA vector expressing retinaldehyde dehydrogenase 2 (RALDH2), the rate-limiting enzyme in RA biosynthesis, could similarly provide enhanced programming of mucosal homing to T cell responses while avoiding teratogenic effects. |
|
Preparation |
Administered as a RALDH2-expressing plasmid during immunization. |
|
Function |
Administration of a RALDH2- expressing plasmid during immunization with a HIVgag DNA vaccine resulted in increased systemic and mucosal CD8+ T cell numbers with an increase in both effector and central memory T cells. |
|
Safety |
Avoids the teratogenic effects associated with high doses of all-trans retinoic acid (ATRA). |
| References |
Holechek et al., 2016: Holechek SA, McAfee MS, Nieves LM, Guzman VP, Manhas K, Fouts T, Bagley K, Blattman JN. Retinaldehyde dehydrogenase 2 as a molecular adjuvant for enhancement of mucosal immunity during DNA vaccination. Vaccine. 2016; 34(46); 5629-5635. [PubMed: 27670072].
|
|
